Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries EQRx, Inc. - Common Stock (NQ: EQRX ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Nov 8, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 1.760 (5) Ask (Size) 2.800 (1) Prev. Close 2.340 Today's Range N/A - N/A 52wk Range 2.300 - 2.500 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX October 06, 2023 From Kahn Swick & Foti, LLC Via Business Wire EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders September 27, 2023 From Robbins LLP Via Business Wire Performance More News Read More BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID), EQRx, Inc. (Nasdaq - EQRX) August 10, 2023 From Brodsky & Smith LLC Via GlobeNewswire Earnings Outlook For EQRx May 05, 2023 Via Benzinga EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX August 02, 2023 From Kahn Swick & Foti, LLC Via Business Wire Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session August 01, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session August 01, 2023 Via Benzinga Revolution Medicines To Acquire EQRx In All-Stock Transaction To Gain Over $1B In Additional Capital August 01, 2023 Via Benzinga Caterpillar, Oshkosh, AudioCodes And Other Big Stocks Moving Higher On Tuesday August 01, 2023 Via Benzinga EQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to Shareholders August 01, 2023 From Halper Sadeh LLC Via Business Wire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session August 01, 2023 Via Benzinga Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital August 01, 2023 From Revolution Medicines, Inc.; EQRx, Inc. Via GlobeNewswire Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC May 13, 2023 Via Talk Markets EQRx Announces Massive Strategic Reset, Slashes Pipeline & Workforce May 09, 2023 Via Benzinga EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results May 08, 2023 From EQRx, Inc. Via GlobeNewswire EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023 April 27, 2023 From EQRx, Inc. Via GlobeNewswire EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders April 21, 2023 From Robbins LLP Via Business Wire EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress February 23, 2023 From EQRx, Inc. Via GlobeNewswire EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From EQRx, Inc. Via GlobeNewswire EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer December 19, 2022 From EQRx, Inc. Via GlobeNewswire Stocks That Hit 52-Week Lows On Wednesday December 14, 2022 Via Benzinga EQRx Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer December 02, 2022 From EQRx, Inc. Via GlobeNewswire Week In Review: Insilico Signs Six-Drug Discovery Deal With Sanofi Worth Up To $1.2 Billion November 12, 2022 Via Talk Markets Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2022 November 11, 2022 Via Benzinga BP To Rally Around 22%? Plus This Analyst Predicts $47 For YETI November 11, 2022 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
